TABLE 2.
Baseline characteristics of the study population.
Study ID | Study arm | Sample | Age, year | Sex, male | FEV1 reversibility % | Nasal polyposis history | Former smoker | Allergic condition |
---|---|---|---|---|---|---|---|---|
Bacharier et al., 2021 | Dupilumab 100–200 mg q2w | 273 | 8.9 ± 1.7 | 175 (64.1) | 21.56 ± 22.43 | — | — | — |
Placebo | 135 | 8.9 ± 1.6 | 87 (64.4) | 15.63 ± 16.33 | — | — | — | |
Castro et al., 2018, Castro et al., 2020, Corren et al., 2019, Corren et al., 2021 | Dupilumab 300 mg q2w | 633 | 47.7 ± 15.6 | 239 (37.8) | 26.29 ± 21.73 | 145 (22.9) | 116 (18.3) | 524 (82.8) |
Placebo | 321 | 48.2 ± 14.7 | 103 (32.1) | 25.73 ± 17.65 | 80 (24.9) | 67 (20.9) | 266 (82.9) | |
Dupilumab 200 mg q2w | 631 | 47.9 ± 15.3 | 244 (38.7) | 27.39 ± 22.79 | 141 (22.3) | 126 (20.0) | 509 (80.7) | |
Placebo | 317 | 48.2 ± 15.6 | 119 (37.5) | 25.06 ± 18.76 | 73 (23.0) | 59 (18.6) | 266 (83.9) | |
Laidlaw et al., 2021 and Bachert et al., 2020 | Dupilumab 300 mg q2w | 258 | 34.78 ± 16.01 | 210 (49.1) | — | 428 (100) | — | — |
Placebo | 170 | — | — | — | ||||
Rape et al., 2018 | Dupilumab 300 mg q2w | 103 | 51.9 ± 12.5 | 41 (40) | — | 33 (32) | 24 (23) | 10 (10) |
Placebo | 107 | 50.7 ± 12.8 | 42 (39) | — | 38 (36) | 17 (16) | 10 (9) | |
Tohda et al., 2020 | Dupilumab 300 mg q2w | 41 | 47.2 ± 18.2 | 13 (31.7) | 20.11 ± 17.54 | 8 (19.5) | 4 (9.8) | 36 (87.8) |
Placebo | 17 | 51.4 ± 12.9 | 5 (29.4) | 21.55 ± 17.95 | 7 (41.2) | 6 (35.3) | 13 (76.5) | |
Dupilumab 200 mg q2w | 37 | 49 ± 16 | 19 (51.4) | 20.63 ± 19.64 | 12 (32.4) | 10 (27.0) | 33 (89.2) | |
Placebo | 19 | 47.1 ± 16.9 | 8 (42.1) | 21 ± 11.44 | 2 (10.5) | 6 (31.6) | 18 (94.7) | |
Wechsler et al., 2021 | Dupilumab 300 mg | 75 | 51.3 ± 12.7 | 34 (45) | 13.32 ± 11.76 | — | 14 (19) | 66 (88) |
Placebo | 74 | 47 ± 11.4 | 27 (36) | 15.58 ± 15.84 | — | 17 (9) | 67 (91) | |
Weinstein et al. 2018- with PAR | Dupilumab 300 mg q2w | 84 | 45 ± 13.2 | 34 (40.5) | — | — | 20 (23.8) | 53 (63.9) |
Dupilumab 200 mg q2w | 73 | 46.6 ± 14.6 | 24 (32.9) | — | — | 17 (23.3) | 54 (75) | |
Placebo | 84 | 47.9 ± 12.9 | 34 (40.5) | — | — | 18 (21.4) | 59 (71.1) | |
Weinstein et al. 2018- without PAR | Dupilumab 300 mg q2w | 43 | 48.8 ± 11.5 | 8 (18.6) | — | — | 9 (20.9) | 21 (51.2) |
Dupilumab 200 mg q2w | 52 | 55.6 ± 10.5 | 14 (26.9) | — | — | 9 (17.3) | 29 (55.8) | |
Placebo | 56 | 51.9 ± 13.2 | 12 (21.4) | — | — | 13 (23.2) | 30 (56.6) | |
Wenzel et al., 2013 | Dupilumab 300 mg q2w | 52 | 37.8 ± 13.2 | 26 (50) | — | — | — | — |
Placebo | 52 | 41.6 ± 13.1 | 26 (50) | — | — | — | — | |
Wenzel et al., 2016 | Dupilumab 200 mg q4w | 154 | 47.9 ± 13.1 | 67 (43·5) | — | 21 (13·9) | 34 (22·2) | 100 (66·2) |
Dupilumab 300 mg q4w | 157 | 47.9 ± 13.1 | 57 (36·3) | — | 31 (20·0) | 38 (24·2) | 99 (63·9) | |
Dupilumab 200 mg q2w | 157 | 51 ± 13.4 | 54 (36·0) | — | 25 (16·8) | 32 (21·3) | 99 (66·4) | |
Dupilumab 300 mg q2w | 150 | 47.5 ± 12.4 | 54 (34·4) | — | 30 (19·5) | 36 (22·9) | 94 (61·0) | |
Placebo | 157 | 49 ± 12.7 | 54 (34·2) | — | 18 (11·7) | 34 (21·5) | 102 (66·2) |
PAR; perennial allergic rhinitis, FEV1; forced expiratory volume in 1 s. Data are reported as mean ± standard deviation or number (percentage).